Alphavirus expression systems
AssigneeOxford Biomedica (UK) Limited
InventorsJason Slingsby, Kyriacos Mitrophanous, Jonathan Rohll, Alison Lawrie
Life of this patent
Estimating the term…
Abstract
An alpha-lentivirus vector comprising at least one alphaviral component and at least one lentiviral component, wherein the lentiviral component is capable of being packaged into a lentiviral particle after introduction of said vector into a human cell.
Claims16
An alpha-lentivirus vector comprising at least one alphaviral component and at least one lentiviral component, wherein the lentiviral component is capable of being packaged into a lentiviral particle after introduction of said vector into a human cell.
A vector according to any preceding claim wherein the lentiviral component is derived from a lentivirus selected from the group consisting of HIV, SIV, VMV, CAEV, EIAV, FIV and BIV.
A vector according to any preceding claim wherein the alphaviral component is derived from an alphavirus selected from the group consisting of Semliki Forest virus (SFV), Sindbis virus, Ross River virus and Venezuelan, Western and Eastern Equine Encephalitis viruses.
A vector according to any one of the preceding claims wherein the composition comprises an RNA transcription start site for the lentiviral vector, and wherein the nucleotide sequence encoding the lentiviral component is operably linked to a promoter comprising an upstream promoter component located upstream of the RNA transcription start site and a downstream promoter component located downstream of the RNA transcription start site.
An alphavirus particle which contains an alphavirus-lentivirus vector of any preceding claim.
Dependencies are inferred from the claim text.